He joins the team after stints on the investment and operational side of biotech.
Daniel Bode joined the biotech investment team at Angelini Venutres, the corporate VC arm of pharmaceutical company Angelini, as associate.
He most recently was senior analyst at Forbion, where he worked for two years, and had previously worked a two-year stint at gene therapy company STRM.BIO.
He holds a PhD in stem cell biology from the University of Cambridge and an MBA from Quantic school of business and technology.
Angelini Ventures invests in the biotechnology and life sciences. It’s most recent investments include precision oncology company Nuclidium, antidepressant treatment developer Elkedonia and immunotherapy technology startup Therini Bio.
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
